Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

LabCorp Licensing MDNA Liquid Biopsy-Based Prostate Cancer Technology

MDNA Life Sciences announced today an exclusive licensing agreement with Laboratory Corporation of America for a liquid biopsy-based noninvasive test... Read More

Cigna to Cover GenomeDx’s Decipher Prostate Cancer Tests

GenomeDx announced today that it has received a positive coverage determination for its Decipher RP and Decipher Biopsy prostate cancer... Read More

MDxHealth Licenses Prognostic Prostate Cancer Biomarker From Philips

MDxHealth announced today that it has signed a worldwide licensing agreement with Philips for the rights to manufacture and market... Read More

Prostate Cancer Study Suggests Patients With DNA Repair Mutations May Benefit From Immunotherapy

A team led by the Institute of Cancer Research in the UK has used exome sequencing in an effort to... Read More

Long Non-Coding RNA Could Serve as Treatment Target for Prostate Cancer

Researchers have uncovered a long non-coding RNA that is associated with androgen receptor signaling in prostate cancer progression and might... Read More

Prostate Cancer Genetic Biomarker May Predict Response to Additional Treatments

Researchers at the Cleveland Clinic and colleagues have found that a testosterone-associated genetic variant can serve as a biomarker to... Read More

Berg, DoD Using AI Platform to Ready Diagnostic Test for Prostate Cancer

A longstanding collaboration between bioinformatics firm Berg and the US Department of Defense is getting ready to bear fruit. Read... Read More

GenomeDx Prostate Cancer Tests Get New York State Approval

GenomeDx announced today that its prostate cancer classifier tests have been approved by the New York State Department of Health’s... Read More

Captured CTCs May Provide Hints to Prostate Cancer Prognosis

Circulating tumor cells (CTCs) and rare, large, blood platelet-producing bone marrow cells called megakaryocytes may provide clues to disease outcomes... Read More

Subscribe to Microarrays & Multiplexing Prostate Cancer Prognosis, Treatment Response Informed by Breast Cancer Expression Signature

A gene expression-based classification signature originally developed for distinguishing luminal and basal breast cancer cases is showing promise classifying prostate... Read More

1 2